Want to join the conversation?
$GILD said in Jan. 2016, it submitted a new drug application in the US and a marketing authorization application in the EU for TAF as a treatment for chronic hepatitis B. Regulatory submissions are also expected in Japan, Korea, Taiwan and India in 2016, and China in 1H17.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.